

## ESH Working Group “Hypertension and the Kidney”

### Board:

Alexandre Persu (Chairman)

Gregor Wuerzner (Secretary)

Peter de Leeuw (Past Chairman)

Patrick Rossignol (Officer in charge of the relationships with ERA/EDTA)

### List of members (June 2016)

NAME	COUNTRY	MAIN INTERESTS	EMAIL
AL SAID Jafar	Bahrain	<ul style="list-style-type: none"><li>✓ HTN and Cardiovascular risk.</li><li>✓ CKD and CV risk</li><li>✓ Haemodialysis</li><li>✓ Interventional Nephrology</li></ul>	jafaralsaid@gmail.com
APARICIO Lucas Sebastian	Argentina	<ul style="list-style-type: none"><li>✓ Renovascular Hypertension</li><li>✓ Home Blood Pressure</li><li>✓ Arterial Stiffness</li><li>✓ Hypertension and Transplantation</li></ul>	lucas.aparicio@hospitalitaliano.org.ar
BERBARI Adel E.	Lebanon	<ul style="list-style-type: none"><li>✓ Role of chronic kidney disease in large artery function</li><li>✓ Role of Phosphate in the pathogenesis of arterial stiffness in hypertensive, diabetic, and</li></ul>	ab01@aub.edu.lb

chronic kidney disease patients

COTTONE Santina	Italy	<ul style="list-style-type: none"> <li>✓ Oxidative stress</li> <li>✓ Endothelial activation</li> <li>✓ Microalbuminuria</li> <li>✓ Renal Pathophysiology</li> </ul>	santina.cottone@unipa.it
DE LEEUW P (Past Chairman)	The Netherlands	<ul style="list-style-type: none"> <li>✓ Fibromuscular dysplasia</li> <li>✓ Atherosclerotic renal artery stenosis</li> <li>✓ Renal impairment/insufficiency</li> <li>✓ Renin-angiotensin system</li> <li>✓ Sodium homeostasis</li> </ul>	p.deleeuw@maastrichtuniversity.nl
DELLES Christian	United Kingdom	<ul style="list-style-type: none"> <li>✓ Hypertension</li> <li>✓ Diabetic nephropathy</li> <li>✓ CKD and CV risk.</li> <li>✓ Pre-eclampsia</li> </ul>	Christian.Delles@glasgow.ac.uk
DHAUN Neeraj (Bean)	United Kingdom	<ul style="list-style-type: none"> <li>✓ Arterial stiffness</li> <li>✓ Hypertension and CKD</li> <li>✓ Hypertension and ESRD</li> </ul>	bean.dhaun@ed.ac.uk
FARAH Raymond	Israël	<ul style="list-style-type: none"> <li>✓ Inflammatory markers</li> <li>✓ Renal failure</li> <li>✓ Diabetes and metabolic syndrome</li> </ul>	raymond.f@ziv.health.gov.il
FAUVEL Jean-Pierre	France	<ul style="list-style-type: none"> <li>✓ CKD</li> <li>✓ Hyperaldosteronism</li> <li>✓ Nephroprotection</li> <li>✓ Diabetic nephropathy</li> <li>✓ Bayesian model (statistics)</li> <li>✓ GFR measurement</li> <li>✓ Stress and hypertension</li> </ul>	jean-pierre.fauvel@chu-lyon.fr

FUJITA Toshiro	Japan	<ul style="list-style-type: none"> <li>✓ Aldosterone</li> <li>✓ Mineralocorticoid receptor</li> <li>✓ Salt-sensitive hypertension</li> <li>✓ Renal sodium transporters</li> </ul>	Toshiro.FUJITA@rcast.u-tokyo.ac.jp
HALIMI Jean-Michel	France	<ul style="list-style-type: none"> <li>✓ Renin angiotensin system</li> <li>✓ Renal transplantation</li> <li>✓ Nephroprotection</li> <li>✓ Diabetic nephropathy</li> <li>✓ Immune cells in hypertension</li> <li>✓ Biomarkers</li> </ul>	jean-michel.halimi@univ-tours.fr
JARRAYA Faïçal	Tunisia	<ul style="list-style-type: none"> <li>✓ Hypertension (education, hypertension and kidney, epidemiology)</li> <li>✓ Diabetic nephropathy</li> <li>✓ Nephroprotection</li> <li>✓ Dialysis</li> </ul>	jarraya_faical@yahoo.fr
JELAKOVIC Bojan	Croatia	<ul style="list-style-type: none"> <li>✓ Prehypertension</li> <li>✓ Balkan endemic nephropathy</li> <li>✓ Arterial stiffness</li> <li>✓ Chronic kidney diseases</li> <li>✓ Cardiovascular risk.</li> </ul>	jelakovicbojan@gmail.com
KROON Bram	The Netherlands	<ul style="list-style-type: none"> <li>✓ Fibromuscular dysplasia,</li> <li>✓ Atherosclerotic renal artery stenosis</li> <li>✓ Chronic kidney disease</li> <li>✓ Treatment resistant hypertension</li> <li>✓ Device-based treatment of hypertension</li> <li>✓ Arterial stiffness</li> </ul>	aa.kroon@mumc.nl
LENGELE Jean-Philippe	Belgium	<ul style="list-style-type: none"> <li>✓ Fibromuscular dysplasia</li> <li>✓ Atherosclerotic renal artery stenosis</li> </ul>	jplengele@yahoo.com

		<ul style="list-style-type: none"> <li>✓ Resistant hypertension</li> <li>✓ HTN and CKD or ESRD</li> </ul>	
Gérard LONDON	France	<ul style="list-style-type: none"> <li>✓ Arterial stiffness</li> <li>✓ Vascular calcifications</li> <li>✓ Chronic Kidney Disease.</li> <li>✓ Haemodialysis</li> </ul>	gerard.london@ch-manhes.fr
MARK Patrick	United Kingdom	<ul style="list-style-type: none"> <li>✓ Fibromuscular dysplasia</li> <li>✓ Atherosclerotic renal artery stenosis</li> <li>✓ Cardio-renal failure</li> <li>✓ Renal perfusion techniques</li> <li>✓ Imaging of cardiac damage in CKD</li> </ul>	patrick.mark@glasgow.ac.uk
MEDIAVILLA Juan Diego	Spain	<ul style="list-style-type: none"> <li>✓ Fibromuscular dysplasia</li> <li>✓ Atherosclerotic renal artery stenosis</li> <li>✓ Diabetes</li> <li>✓ Microalbuminuria</li> </ul>	jdmediavillag@hotmail.com
MORGANTI Alberto	Italy	<ul style="list-style-type: none"> <li>✓ Renovascular hypertension</li> <li>✓ Hyperaldosteronism</li> <li>✓ Renin/aldo measurement</li> <li>✓ Renin Angiotensin System antagonists</li> </ul>	alberto.morganti@unimi.it
PERSU Alexandre (Chairman)	Belgium	<ul style="list-style-type: none"> <li>✓ Fibromuscular Dysplasia</li> <li>✓ Atherosclerotic renal artery stenosis</li> <li>✓ Resistant Hypertension</li> <li>✓ Renal denervation</li> <li>✓ Nephroprotection</li> <li>✓ Pheochromocytoma</li> </ul>	alexandre.persu@uclouvain.be
PLOUIN Pierre-François	France	<ul style="list-style-type: none"> <li>✓ Fibromuscular dysplasia</li> <li>✓ Atherosclerotic renal artery stenosis</li> <li>✓ Randomized controlled trial</li> <li>✓ von Hippel Lindau disease</li> </ul>	pierre-francois.plouin@aphp.fr

PONTREMOLI Roberto	Italy	<ul style="list-style-type: none"> <li>✓ Hypertensive organ damage</li> <li>✓ Cardiovascular and renal risk</li> </ul>	roberto.pontremoli@unige.it
PRUIJM Menno	Switzerland	<ul style="list-style-type: none"> <li>✓ Mechanisms (including hypertension) underlying the development and progression of chronic kidney disease</li> <li>✓ Renal Imaging (Doppler ultrasound and BOLD-MRI)</li> <li>✓ Cohort studies</li> </ul>	mennopruijm@hotmail.com
ROBLES Nicolas Roberto	Spain	<ul style="list-style-type: none"> <li>✓ Hypertension</li> <li>✓ Diabetic nephropathy</li> <li>✓ Chronic kidney disease</li> <li>✓ Geriatric nephrology</li> </ul>	nrrobles@yahoo.es
ROSIVALL Laszlo	Hungary	<ul style="list-style-type: none"> <li>✓ Regulation of Intrarenal Hemodynamics</li> <li>✓ Function and Morphology of Juxtaglomerular apparatus</li> <li>✓ Intrarenal Renin-Angiotensin System</li> <li>✓ RBF, GFR autoregulation</li> <li>✓ Microcirculation, Vasoactive Mediators and Tissue</li> <li>✓ Target organ Damage</li> <li>✓ Mechanism of Chronic Rejection of the Transplanted Kidney</li> <li>✓ Mechanism of Intracellular Signal Transduction</li> <li>✓ Role of Na/K/ATP-ase in Renal Haemodynamics</li> <li>✓ Intracellular signal transmission,</li> <li>✓ Pathomechanism of tissue fibrosis, glomerulosclerosis</li> <li>✓ Nanomedicine</li> </ul>	rosivall@net.sote.hu

ROSSIGNOL Patrick (Relationships ERA/EDTA)	France	<ul style="list-style-type: none"> <li>✓ Clinical trials</li> <li>✓ Biomarkers</li> <li>✓ Chronic Kidney Disease</li> <li>✓ Hypertension</li> <li>✓ Cardiorenal syndrome</li> </ul>	p.rossignol@chu-nancy.fr
VAN DER NIEPEN Patricia	Belgium	<ul style="list-style-type: none"> <li>✓ Epidemiology of Hypertension</li> <li>✓ Out-of-office blood pressure measurements (24h ABPM &amp; HBPM - telemedicine)</li> <li>✓ Salt and hypertension</li> <li>✓ Fibromuscular dysplasia</li> <li>✓ Atherosclerotic renal artery stenosis</li> <li>✓ HTN in CKD, especially dialysis related, and ADPKD</li> <li>✓ Hypertension in pregnancy</li> <li>✓ Resistant HTN</li> </ul>	hemovnp@uzbrussel.be
VOGT Liffert	The Netherlands	<ul style="list-style-type: none"> <li>✓ Sodium homeostasis</li> <li>✓ Proteinuria</li> <li>✓ Endothelial glycosaminoglycans</li> <li>✓ Microcirculation</li> </ul>	l.vogt@amc.uva.nl
WEBB David John	United Kingdom	<ul style="list-style-type: none"> <li>✓ Novel therapeutics</li> <li>✓ Endothelial function</li> <li>✓ Renal inflammation/fibrosis</li> <li>✓ Resistant hypertension</li> <li>✓ Arterial stiffness</li> <li>✓ Hypertension and CKD</li> </ul>	D.J.Webb@ed.ac.uk
WUERZNER Gregor	Switzerland	<ul style="list-style-type: none"> <li>✓ Interaction between RAS, SNS and kidney</li> <li>✓ Obesity related hypertension, renal</li> </ul>	gregoire.wuerzner@chuv.ch

(Secretary)

mechanisms

ZOCCALI Carmine

Italy

- ✓ Hypertension in CKD
- ✓ Cardiovascular risk in CKD
- ✓ Biomarkers of Cardiorenal risk
- ✓ ESRD and uremic toxicity
- ✓ Epidemiology of CKD and Hypertension
- ✓ 24h-ABPM in CKD
- ✓ Sympathetic overactivity in CKD
- ✓ Renal denervation

[carmine.zoccali@tin.it](mailto:carmine.zoccali@tin.it)

## **Statutes of the Working Group “Hypertension and the Kidney”**

### **Article 1.**

The working group (WG HT & Kidney) is established as a working group of the European Society of Hypertension (ESH) according to the by-laws of the ESH. The internal governance of the WG is regulated by ESH Council-approved Rules and Regulations.

### **Article 2.**

The WG encourages research, teaching, and communication of knowledge, and participates in education focused on the effects of high blood pressure and associated cardiovascular risk factors on the Kidney.

Specific objectives include:

- To contribute to the organization of the scientific program of the annual ESH Congress and to support and participate in other ESH scientific meetings and symposia
- To contribute to task forces for the development and implementation of ESH guidelines and joint guidelines with sister societies
- To develop position papers and consensus documents on hypertension and the kidney in collaboration with sister societies
- To contribute to the organization of joint sessions with other international societies and other scientific meetings related to the Kidney

### **Article 3.**

The Board consists of:

- Officers: Chair, immediate Past-Chair, Secretary, and up to five officers.

The Chair and the Secretary are elected for a non-renewable period of 4 years (2 years + 2 years if no other candidate applies). The Chair automatically becomes Past-Chair for the following 4 years, after his/her term of office has expired. The Past-Chair has an advisory role.

The officers are appointed by the Chair for the duration of his mandate. Approval from the majority of the WG is necessary. Officers have to be members of the WG in order to be appointed.

#### **Article 4.**

The Secretary, with the agreement of the Chair, is responsible for preparing an annual report on the activities of the WG for the ESH Council and the membership, to be presented and approved at the Annual General Assembly.

#### **Article 5.**

The members of the WG will elect the Chair and Secretary every 4 years, unless a new candidate applies after 2 years of the mandate. In this case a vote is organized after 2 years.

#### **Article 6.**

The Board will consist of members with a proven record in the field of hypertension and the Kidney. Potential members should apply to the Chair by submitting a brief (one page) curriculum vitae including relevant references related to the subject of the working group. The Chair will ratify the application, but may ask for advice from the other Officers if deemed appropriate.

#### **Article 7.**

The Board will meet at least once a year at the annual ESH Congress. The Board may meet in conjunction with other events and hold conference calls when required.

#### **Article 8.**

The General Assembly will be held once a year during the annual ESH Congress. The agenda of the General Assembly will be drawn up by the Chair.